Natural products and their derivatives
provide a promising source
for drug discoveries. However, several natural products and derivatives
are still difficult to advance to in vivo drug testing
due to the requirement of an ample supply of drug candidates. Herein,
we describe an immobilized enzyme cascade for the scalable continuous
production of neuropharmaceutical prodrugs, L-4-chlorokynurenine
(L-4-Cl-Kyn) and its non-natural analogue L-4-Br-Kyn. This synthetic route features a highly efficient
one-pot C–H activation/oxidation/hydrolyzation cascade for
the assembly of the Kyn core structure, inexpensive substituted aryl
sources for the abundance of Kyn scaffold types, and easily available
gram-scale MOF–hydrogel hybrid material for the immobilization
of enzymes to recycle biocatalysts and maximize their catalytic efficiency.
As a result, our method accumulates 370 mg of L-4-Cl-Kyn
and 365 mg of L-4-Br-Kyn, 250 mL product volume per
cycle for 5 cycles, which is nearly twice the yield of free enzymatic
catalysis in the same enzyme amount frame. Therefore, this study establishes
the applicability of synthetic biology strategies and immobilization
biotechnology in synthesizing high value-added chemicals and narrows
the gap in moving cell-free immobilized enzyme cascade systems from
academic studies to industrial applications. Moreover, animal experiments
demonstrate that L-4-Br-Kyn displays a slightly better
antidepressant effect than the phase II drug L-4-Cl-Kyn,
which further emphasizes the importance of our work for the facile
scale-up synthesis to provide large amounts of pharmaceutical products
in facilitating the development or discovery of drug candidates. These
practical features of our study will undoubtedly be welcomed by academic
and industrial researchers.